India, Sept. 27 -- HUTCHMED (China) Limited (HCM) on Monday announced the initiation of the Phase 1a portion of a global clinical trial evaluating HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors.
HUTCHMED said the first patient received the first dose in China on September 24, 2026.
HMPL-A830 is an investigational Antibody-Targeted Therapy Conjugate (ATTC) comprising a highly selective KRAS small-molecule inhibitor payload conjugated to an anti-EGFR antibody. The therapy is designed to deliver the KRAS inhibitor directly to EGFR-expressing tumors while simultaneously blocking EGFR and KRAS signaling.
According to the company, the clinical development program will initially focus on colorectal, pancreatic and ...